3,4-dihydroxyphenylacetaldehyde has been researched along with nifedipine in 1 studies
Studies (3,4-dihydroxyphenylacetaldehyde) | Trials (3,4-dihydroxyphenylacetaldehyde) | Recent Studies (post-2010) (3,4-dihydroxyphenylacetaldehyde) | Studies (nifedipine) | Trials (nifedipine) | Recent Studies (post-2010) (nifedipine) |
---|---|---|---|---|---|
99 | 0 | 50 | 16,024 | 2,496 | 1,505 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hashimoto, T; Yabe-Nishimura, C | 1 |
1 other study(ies) available for 3,4-dihydroxyphenylacetaldehyde and nifedipine
Article | Year |
---|---|
Oxidative metabolite of dopamine, 3,4-dihydroxyphenylacetaldehyde, induces dopamine release from PC12 cells by a Ca2+-independent mechanism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Calcium; Calcium Channel Blockers; Dopamine; L-Lactate Dehydrogenase; Nifedipine; Oxidation-Reduction; Parkinson Disease; PC12 Cells; Rats | 2002 |